About 40 million people suffer from lactose intolerance in America. If Ritter Pharmaceuticals Inc. has any say, that number will soon be zero. CEO Andrew Ritter ......
LOS ANGELES, CA / ACCESSWIRE / November 28, 2016 / Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company") develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product, RP-G28, is being developed as potentially the first FDA-approved treatment for lactose intolerance. The Company announced today that it will be presenting at the 9th Annual LD Micro Main Event on Wednesday, December 7, 2016 at 11 am...